These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 10868128)

  • 1. Thalidomide--a treatment for cancer?
    Mayo Clin Health Lett; 2000 Jun; 18(6):4. PubMed ID: 10868128
    [No Abstract]   [Full Text] [Related]  

  • 2. Thalidomide shows promise as cancer treatment.
    Health News; 2000 Jan; 6(1):8. PubMed ID: 11019665
    [No Abstract]   [Full Text] [Related]  

  • 3. Thalidomide in the treatment of multiple myeloma.
    Rajkumar SV
    Expert Rev Anticancer Ther; 2001 Jun; 1(1):20-8. PubMed ID: 12113124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the use of thalidomide as an antiangiogenic agent in the treatment of multiple myeloma.
    Ribatti D; Vacca A
    Ann Hematol; 2003 Apr; 82(4):262. PubMed ID: 12707735
    [No Abstract]   [Full Text] [Related]  

  • 5. [Thalidomide and others: new treatment for myeloma].
    Malphettes M; Fermand JP
    Rev Prat; 2003 Oct; 53(15):1633-5. PubMed ID: 14689905
    [No Abstract]   [Full Text] [Related]  

  • 6. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma.
    Rajkumar SV; Witzig TE
    Cancer Treat Rev; 2000 Oct; 26(5):351-62. PubMed ID: 11006136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thalidomide.
    Waldman AR
    Clin J Oncol Nurs; 2000; 4(2):99-100. PubMed ID: 11107384
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and safety of thalidomide in the treatment of multiple myeloma.
    Warzocha K; Kraj M; Pogłód R; Szpila T; Mendek-Czajkowska E; Chełstowska M; Tronina RH
    Acta Pol Pharm; 2008; 65(6):771-4. PubMed ID: 19172865
    [No Abstract]   [Full Text] [Related]  

  • 9. [Thalidomide for the treatment of refractory multiple myeloma].
    Kakimoto T; Hattori Y; Okamoto S
    Rinsho Ketsueki; 2002 May; 43(5):345-8. PubMed ID: 12096483
    [No Abstract]   [Full Text] [Related]  

  • 10. Low-dose of thalidomide in the treatment of refractory myeloma.
    Pini M; Baraldi A; Pietrasanta D; Allione B; Depaoli L; Salvi F; Levis A
    Haematologica; 2000 Oct; 85(10):1111-2. PubMed ID: 11025615
    [No Abstract]   [Full Text] [Related]  

  • 11. [Multiple myeloma: the role of angiogenesis and therapeutic application of thalidomide].
    Jurczyszyn A; Wolska-Smoleń T; Skotnicki AB
    Przegl Lek; 2003; 60(8):542-7. PubMed ID: 14974349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thalidomide--a revival story.
    Raje N; Anderson K
    N Engl J Med; 1999 Nov; 341(21):1606-9. PubMed ID: 10564693
    [No Abstract]   [Full Text] [Related]  

  • 13. [Thalidomide: (re)discovery of a not very dear old molecule].
    Bressoud A; Schwab BZ
    Rev Med Suisse Romande; 2003 Apr; 123(4):238-40. PubMed ID: 15088555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Why not start with thalidomide?
    Loprinzi C; Rajkumar SV
    J Clin Oncol; 2003 Jun; 21(11):2211-4. PubMed ID: 12775748
    [No Abstract]   [Full Text] [Related]  

  • 15. Correspondence re: J. Lu et al., thalidomide metabolites in mice and patients with multiple myeloma. Clin. Cancer Res., 9: 1680-1688, 2003.
    Zhou S
    Clin Cancer Res; 2003 Nov; 9(14):5429; author reply 5429. PubMed ID: 14614031
    [No Abstract]   [Full Text] [Related]  

  • 16. Thalidomide: present and future in multiple myeloma.
    Hussein MA
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):25-31. PubMed ID: 15757435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment.
    Du W; Hattori Y; Hashiguchi A; Kondoh K; Hozumi N; Ikeda Y; Sakamoto M; Hata J; Yamada T
    Pathol Int; 2004 May; 54(5):285-94. PubMed ID: 15086832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Bone marrow angiogenesis in multiple myeloma: new insights into the pathogenesis, and development of a new therapeutic approach].
    Hattori Y; Kakimoto T
    Rinsho Ketsueki; 2000 May; 41(5):426-9. PubMed ID: 10879105
    [No Abstract]   [Full Text] [Related]  

  • 19. Thalidomide and lenalidomide in the treatment of multiple myeloma.
    Kumar S; Rajkumar SV
    Eur J Cancer; 2006 Jul; 42(11):1612-22. PubMed ID: 16750621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correspondence re: K. Neben et al., high plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin. Cancer Res., 7: 2675-2681, 2001.
    Go RS; Horstman AL
    Clin Cancer Res; 2002 Aug; 8(8):2750; author reply 2751. PubMed ID: 12171909
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.